Title: [FibroTest-ActiTest for predicting liver fibrosis and inflammatory activity in Chinese patients with chronic hepatitis B].
Abstract: Objectives To confirm the diagnostic value ofFibroTest-ActiTest (FT-AT) in predicting fiver fibrosis and inflammatory activity in patients with chronic hepatitis B (CHB), and to study the discor-dances between FT and their liver biopsies. Methods A study was performed on 100 patients with CHB who underwent liver biopsies in our hospital. Serum samples for biochemical markers were taken on the day of their biopsies. Diagnostic accuracies were assessed by ROC curve analysis. Results The median biopsy specimen size was 15mm (range: 8-30), with 9 (median) portal tracts (range 5-26). Thirty-nine patients were classified as Ishak F3-F6 in fibrosis and 65 patients as A2-A4 in inflammation. Areas under ROC curve for diagnosis of significant inflammation (A2-A4), significant fibrosis (F3-F6), and cirrhosis (F5-F6) were 0.833 (95% CI: 0.753-0.913), 0.840 (0.750-0.929), and 0.862 (0.721-1.003), respectively. FT < 0.31 had a NPV of 86% for excluding significant fibrosis, whereas FT ≥ 0.72 had a PPV of 92% for predicting significant fibrosis. Among the 26 patients with 2 fibrosis stages of discordances between FT and biopsy, the discordance was attributable to biopsy in 3 cases, to FT in 7, and undetermined in 16. Conclusion This study confirms the diagnostic value of FT-AT and suggests that 68% of our patients with CHB can be reliably identified by FT without a liver biopsy and with a dignosis accuracy of 87%.
Key words:
Hepatitis B, chronic; Liver fibrosis; Diagnosis, noninvasive; ROC curve; FibroTest-ActiTest
Publication Year: 2008
Publication Date: 2008-12-01
Language: en
Type: article
Indexed In: ['pubmed']
Access and Citation
Cited By Count: 5
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot